Exact Mass: 604.3445124
Exact Mass Matches: 604.3445124
Found 272 metabolites which its exact mass value is equals to given mass value 604.3445124,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
[(S)-1-Carboxy-2-phenyl-ethyl]-carbamoyl-Arg-Val-Arg-aldehyde
Dilazep
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist C - Cardiovascular system > C01 - Cardiac therapy > C01D - Vasodilators used in cardiac diseases D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents
Telinavir
PA(10:0/18:1(12Z)-O(9S,10R))
PA(10:0/18:1(12Z)-O(9S,10R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/18:1(12Z)-O(9S,10R)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 9,10-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(18:1(12Z)-O(9S,10R)/10:0)
PA(18:1(12Z)-O(9S,10R)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(12Z)-O(9S,10R)/10:0), in particular, consists of one chain of one 9,10-epoxy-octadecenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(10:0/18:1(9Z)-O(12,13))
PA(10:0/18:1(9Z)-O(12,13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/18:1(9Z)-O(12,13)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 12,13-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(18:1(9Z)-O(12,13)/10:0)
PA(18:1(9Z)-O(12,13)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(9Z)-O(12,13)/10:0), in particular, consists of one chain of one 12,13-epoxy-octadecenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
methyl-ent-15alpha-acetoxy-1alpha-(2-methyl-2,3-epoxybutyryloxy)-9alpha-hydroxy-7alpha-isovaleryloxykaur-16-en-19-oate|methyl-ent-15alpha-acetoxy-1alpha-<2-methyl-2,3-epoxybutyryloxy>-9alpha-hydroxy-7alpha-isovaleryloxykaur-16-en-19-oate
(5alpha,7alpha,13alpha17alpha,20S,23R,24R)-21,25-epoxy-23,24-dihydroxy-4,4,8-trimethyl-3-oxocholesta-1,14-dien-7-yl benzeneacetic acid ester|turrapubesol C
(3R,5aR,5bR,6R,7S,9S,11aS,12R,13bS)-12-(acetyloxy)icosahydro-7,9-dihydroxy-5a,5b,11a,13b-tetramethyl-8-methylidene-3-(prop-1-en-2-yl)-1H-cyclopenta[a]chrysen-6-yl benzoate|11alpha-(acetyloxy)-7beta-(benzoyloxy)-21alphaH-24-norhopa-4(23),22(29)-diene-3beta,6beta-diol|cavalerol B
(3R,5aR,5bR,6R,7S,9S,11aR,12S,13bS)-7-(acetyloxy)icosahydro-9,12-dihydroxy-5a,5b,11a,13b-tetramethyl-8-methylidene-3-(prop-1-en-2-yl)-1H-cyclopenta[a]chrysen-6-yl benzoate|6beta-(acetyloxy)-7beta-(benzoyloxy)-21alphaH-24-norhopa-4(23),22(29)-diene-3beta,11beta-diol|cavalerol G
14beta-hydrogen-(20S,22R)-22,26-epoxy-27-[(beta-glucopyranosyl)oxy]ergosta-2,4,6,24-tetraene-1,26-dione|baimantuoluoside H
(1R*,3S*,5S*,6aR*,7R*,8R*,9S*,10S*,10aR*)-1,10-bis(acetyloxy)-5-methoxy-7,8-dimethyl-7-[(2Z)-3-methylpenta-2,4-dien-1-yl]-3,5,6,6a,7,8,9,10-octahydronaphtho[1,8a-c]furan-3,9-diyl dibutanoate
(21alpha-H)-24-norneohopa-4(23),22(29)-diene-3beta,6beta,7beta-triol 7-caffeate
caseamembrin R|rel-(2S,5R,6S,7R,8S,9S,10R,18S,19R)-2-(2-methylbutanoyloxy)-18-butanoyloxy-7,19-diacetoxy-18,19-epoxy-6,7-dihydroxy-cleroda-3,13(16),14-triene
(5alpha,7alpha,13alpha,17alpha,20S,23R,24R)-21,24-epoxy-23,25-dihydroxy-4,8,8-trimethyl-3-oxocholesta-1,14-dien-7-yl benzeneacetic acid ester|turrapubesol B
C33H48O10_(2alpha,5alpha,9alpha,10beta,14beta)-2,5,9,10-Tetraacetoxytaxa-4(20),11-dien-14-yl 2-methylbutanoate
Phe Pro Arg Trp
Phe Pro Trp Arg
Phe Arg Pro Trp
Phe Arg Trp Pro
Phe Trp Pro Arg
Phe Trp Arg Pro
His His Arg Arg
His Arg His Arg
His Arg Arg His
Ile Met Arg Trp
Ile Met Trp Arg
Ile Arg Met Trp
Ile Arg Trp Met
Ile Thr Trp Trp
Ile Trp Met Arg
Ile Trp Arg Met
Ile Trp Thr Trp
Ile Trp Trp Thr
Leu Met Arg Trp
Leu Met Trp Arg
Leu Arg Met Trp
Leu Arg Trp Met
Leu Thr Trp Trp
Leu Trp Met Arg
Leu Trp Arg Met
Leu Trp Thr Trp
Leu Trp Trp Thr
Met Ile Arg Trp
Met Ile Trp Arg
Met Leu Arg Trp
Met Leu Trp Arg
Met Arg Ile Trp
Met Arg Leu Trp
Met Arg Trp Ile
Met Arg Trp Leu
Met Trp Ile Arg
Met Trp Leu Arg
Met Trp Arg Ile
Met Trp Arg Leu
Pro Phe Arg Trp
Pro Phe Trp Arg
Pro Arg Phe Trp
Pro Arg Trp Phe
Pro Trp Phe Arg
Pro Trp Arg Phe
Arg Phe Pro Trp
Arg Phe Trp Pro
Arg His His Arg
Arg His Arg His
Arg Ile Met Trp
Arg Ile Trp Met
Arg Leu Met Trp
Arg Leu Trp Met
Arg Met Ile Trp
Arg Met Leu Trp
Arg Met Trp Ile
Arg Met Trp Leu
Arg Pro Phe Trp
Arg Pro Trp Phe
Arg Arg His His
Arg Trp Phe Pro
Arg Trp Ile Met
Arg Trp Leu Met
Arg Trp Met Ile
Arg Trp Met Leu
Arg Trp Pro Phe
Thr Ile Trp Trp
Thr Leu Trp Trp
Thr Trp Ile Trp
Thr Trp Leu Trp
Thr Trp Trp Ile
Thr Trp Trp Leu
Trp Phe Pro Arg
Trp Phe Arg Pro
Trp Ile Met Arg
Trp Ile Arg Met
Trp Ile Thr Trp
Trp Ile Trp Thr
Trp Leu Met Arg
Trp Leu Arg Met
Trp Leu Thr Trp
Trp Leu Trp Thr
Trp Met Ile Arg
Trp Met Leu Arg
Trp Met Arg Ile
Trp Met Arg Leu
Trp Pro Phe Arg
Trp Pro Arg Phe
Trp Arg Phe Pro
Trp Arg Ile Met
Trp Arg Leu Met
Trp Arg Met Ile
Trp Arg Met Leu
Trp Arg Pro Phe
Trp Thr Ile Trp
Trp Thr Leu Trp
Trp Thr Trp Ile
Trp Thr Trp Leu
Trp Trp Ile Thr
Trp Trp Leu Thr
Trp Trp Thr Ile
Trp Trp Thr Leu
Telinavir
C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C97366 - HIV Protease Inhibitor C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent
(E)-5-hydroxy-2,2,6,6-tetramethylhept-4-en-3-one,manganese
2,7-Dihydroxy-3,6,10,11-tetrakis(pentyloxy)triphenylene
2,4,8,10-Tetraoxa-3,9-diphosphaspiro[5.5]undecane, 3,9-bis[2,4-bis(1,1-dimethylethyl)phenoxy]-
butane-1,4-diol,hexanedioic acid,hexane-1,6-diol,1-isocyanato-4-[(4-isocyanatophenyl)methyl]benzene
N,N-Bis[4-(diethylamino)phenyl]-N,N-diethyl-1,4-benzenediamine hexafluorophosphate
N~1~-{4-[(tert-Butylcarbamoyl)(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl}-N~2~-(quinoline-2-carbonyl)aspartamide
Withalongolide M
A steroid saponin that is the monosaccharide derivative of the 19-norwithanolide. It has been isolated from the aerial parts of Physalis longifolia.
Withalongolide N
A steroid saponin that is the monosaccharide derivative of the 19-norwithanolide. It has been isolated from the aerial parts of Physalis longifolia.
Dilazep
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist C - Cardiovascular system > C01 - Cardiac therapy > C01D - Vasodilators used in cardiac diseases D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents
[(1S,2R,3R,4S,5R)-5-azaniumyl-3-[(2S,3R,4S,5R)-4-[(2R,3R,4R,5S,6S)-3-azaniumyl-6-(azaniumylmethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-2-[(2S,3R,5S,6R)-3-azaniumyl-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-hydroxycyclohexyl]azanium
[(2R)-1-decanoyloxy-3-phosphonooxypropan-2-yl] (Z)-11-(3-pentyloxiran-2-yl)undec-9-enoate
[(2R)-2-decanoyloxy-3-phosphonooxypropyl] (Z)-11-(3-pentyloxiran-2-yl)undec-9-enoate
2-[[(2R)-3-acetyloxy-2-[(6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C30H55NO9P+ (604.3614249999999)
2-[[(2R)-2-acetyloxy-3-[(6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C30H55NO9P+ (604.3614249999999)
2-[[2-[[2-[[1-Azepanyl(oxo)methyl]amino]-4-methyl-1-oxopentyl]amino]-3-(1-methyl-3-indolyl)-1-oxopropyl]amino]-3-(2-pyridinyl)propanoic acid
1-[[(3R,9S,10S)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methyl-3-(1-naphthalenyl)urea
C35H48N4O5 (604.3624517999999)
1-[[(3S,9S,10S)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methyl-3-(1-naphthalenyl)urea
C35H48N4O5 (604.3624517999999)
1-[[(3S,9S,10R)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methyl-3-(1-naphthalenyl)urea
C35H48N4O5 (604.3624517999999)
1-[[(3S,9S,10R)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methyl-3-(1-naphthalenyl)urea
C35H48N4O5 (604.3624517999999)
1-[[(3R,9R,10R)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methyl-3-(1-naphthalenyl)urea
C35H48N4O5 (604.3624517999999)
1-[[(3R,9R,10S)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methyl-3-(1-naphthalenyl)urea
C35H48N4O5 (604.3624517999999)
1-[[(3S,9R,10S)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methyl-3-(1-naphthalenyl)urea
C35H48N4O5 (604.3624517999999)
1-[[(3S,9S,10S)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methyl-3-(1-naphthalenyl)urea
C35H48N4O5 (604.3624517999999)
1-[[(3R,9S,10R)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methyl-3-(1-naphthalenyl)urea
C35H48N4O5 (604.3624517999999)
1-[[(3R,9S,10R)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methyl-3-(1-naphthalenyl)urea
C35H48N4O5 (604.3624517999999)
1-[[(3R,9S,10S)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methyl-3-(1-naphthalenyl)urea
C35H48N4O5 (604.3624517999999)
1-[[(3S,9R,10R)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methyl-3-(1-naphthalenyl)urea
C35H48N4O5 (604.3624517999999)
1-[[(3R,9R,10S)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methyl-3-(1-naphthalenyl)urea
C35H48N4O5 (604.3624517999999)
1-[[(3S,9R,10R)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methyl-3-(1-naphthalenyl)urea
C35H48N4O5 (604.3624517999999)
1-[[(3R,9R,10R)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methyl-3-(1-naphthalenyl)urea
C35H48N4O5 (604.3624517999999)
1-cyclohexyl-3-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]urea
[(6Z,10E,14E)-3,7,11,15,19-pentamethylicosa-6,10,14-trienyl] [(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hydrogen phosphate
(4S,5E,9E,11S,13E,15E,18R)-4-[(2R,3R,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-methoxyoxan-2-yl]oxy-8-methoxy-9,11-dimethyl-18-[(1Z,4E)-2-methylhexa-1,4-dienyl]-1-oxacyclooctadeca-5,9,13,15-tetraen-2-one
[1-[(2-hexanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
[1-[(2-acetyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-octanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
[1-[(2-butanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexanoyloxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
[1-butanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-octanoyloxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
[1-acetyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate
[1-phosphonooxy-3-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate
Cyclic GMP (TBAOH)
Cyclic GMP TBAOH is a tetra-n-butylammonium hydroxide (TBAOH) form of Cyclic GMP (HY-12512). Cyclic GMP is an endogenous second messenger that regulates a variety of cellular processes including apoptosis, vasodilation, and neurotransmission through the activation of signaling pathways such as Protein Kinase G in cells[1].